Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3. Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:CLVS
- CUSIP: 18946410
- Web: www.clovisoncology.com
Capitalization:- Market Cap: $4.21852 billion
- Outstanding Shares: 44,772,000
Average Prices:- 50 Day Moving Avg: $82.45
- 200 Day Moving Avg: $64.60
- 52 Week Range: $13.43 - $96.92
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -43.96
- P/E Growth: -0.48
Sales & Book Value:- Annual Revenue: $7.12 million
- Price / Sales: 547.33
- Book Value: $3.89 per share
- Price / Book: 22.38
Profitability:- EBIDTA: ($262,070,000.00)
- Return on Equity: -322.29%
- Return on Assets: -62.07%
Debt:- Debt-to-Equity Ratio: 1.62%
- Current Ratio: 7.29%
- Quick Ratio: 7.17%
Misc:- Average Volume: 1.90 million shs.
- Beta: 1.53
- Short Ratio: 2.9
Frequently Asked Questions for Clovis Oncology (NASDAQ:CLVS)
What is Clovis Oncology's stock symbol?
Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."
How were Clovis Oncology's earnings last quarter?
Clovis Oncology, Inc. (NASDAQ:CLVS) announced its quarterly earnings data on Wednesday, May, 3rd. The company reported ($1.33) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($1.43) by $0.10. The firm had revenue of $7.05 million for the quarter, compared to analysts' expectations of $6.04 million. View Clovis Oncology's Earnings History.
Where is Clovis Oncology's stock going? Where will Clovis Oncology's stock price be in 2017?
16 brokers have issued twelve-month price objectives for Clovis Oncology's stock. Their predictions range from $23.00 to $125.00. On average, they anticipate Clovis Oncology's stock price to reach $79.50 in the next twelve months. View Analyst Ratings for Clovis Oncology.
What are analysts saying about Clovis Oncology stock?
Here are some recent quotes from research analysts about Clovis Oncology stock:
- 1. According to Zacks Investment Research, "Clovis got a huge boost with the FDA granting accelerated approval to its advanced ovarian cancer treatment, Rubraca in Dec 2016. Rubraca has bright prospects, given the tremendous demand for PARP inhibitors. Successful commercialization will significantly boost Clovis’ sales. Rubraca is also under review in the EU for a comparable indication. Several studies on Rubraca, targeting different types of ovarian cancer patients, are currently underway. Promising progression-free survival and safety results from the ARIEL3 maintenance study is expected to help expand Rubraca’s label. However, with just one approved product in the portfolio, Clovis is heavily dependent on Rubraca for growth, which concerns us. Rubraca is also set to face intense competition from currently marketed PARP inhibitors. Loss estimates have widened lately ahead of the Q2 results. Clovis has a mixed earnings surprise record in the recent quarters." (7/13/2017)
- 2. Cann analysts commented, "We are initiating coverage of Clovis Oncology, a recently commercial-stage biotechnology company, with a Perform rating. We anticipate Clovis will continue to develop its commercial drug, Rubraca (already approved for third-line ovarian cancer), in additional indications. Rubraca (rucaparib) is a PARP inhibitor for the treatment of ovarian cancer. As a therapeutic class, PARP inhibitors—including FDA-approved Lynparza (olaparib) and Zejula (niraparib)—are designed to exploit a synthetically lethal situation in tumors that lack proper DNA repair mechanisms." (6/22/2017)
- 3. Goldman Sachs Group, Inc. (The) analysts commented, "AZN (covered by Keyur Parekh) presented data from a Ph3 SOLO-2 maintenance ovarian cancer trial of Lynparza (PARP inhibitor) on March 14 at the SGO conference, which we believe has implications for CLVS (lead marketed drug Rubraca is also a PARP). CLVS, AZN and TSRO (not covered) all have PARP inhibitors that they are evaluating for use in the maintenance treatment of ovarian cancer." (3/15/2017)
- 4. Stifel Nicolaus analysts commented, "This price assumes about a 40% market share for rucaparib throughout addressable ovarian cancer (OC). However, in deriving this target, we include sales in the maintenance setting for ovarian cancer with a weighting of 75% (some risk remains to ARIEL3) and note that full weighing of this unapproved usage would suggest a fair value of about $104. Furthermore, inclusion of sales in mCRPC, which we consider highly promising but where large trials are just starting, suggests a fair value for Clovis shares of about $182. We consider most of the ongoing trials for rucaparib to be relatively low risk, but with several other players also competing for each indication we believe a takeout price of about 50% of our best case scenario makes sense." (1/23/2017)
Who are some of Clovis Oncology's key competitors?
Some companies that are related to Clovis Oncology include Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), Kite Pharma (KITE), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), BeiGene (BGNE), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC (GWPH), China Biologic Products (CBPO), Agios Pharmaceuticals (AGIO), Prothena Corporation PLC (PRTA), Sarepta Therapeutics (SRPT), AveXis (AVXS), Axovant Sciences (AXON) and Spark Therapeutics (ONCE).
Who are Clovis Oncology's key executives?
Clovis Oncology's management team includes the folowing people:
- M. James E. Barrett Ph.D., Independent Chairman of the Board
- Patrick J. Mahaffy, President, Chief Executive Officer, Director
- Daniel W. Muehl, Senior Vice President of Finance, Principal Accounting Officer and Principal Financial Officer
- Gillian C. Ivers-Read, Executive Vice President - Technical Operations, Chief Regulatory Officer
- Lindsey Rolfe BSc, MB ChB, MRCP, F, Executive Vice President - Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer
- C. Dale Hooks, Senior Vice President, Chief Commercial Officer
- Brian G. Atwood, Independent Director
- James C. Blair Ph.D., Independent Director
- Keith T. Flaherty M.D., Independent Director
- Ginger L. Graham, Independent Director
Who owns Clovis Oncology stock?
Clovis Oncology's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (0.28%), Capital Impact Advisors LLC (0.03%), Insight Capital Research & Management Inc. (0.02%), Aperio Group LLC (0.01%), Hershey Trust Co. (0.01%) and Legacy Private Trust Co. (0.01%). Company insiders that own Clovis Oncology stock include Erle T Mast, Gillian C Ivers-Read and Lindsey Rolfe. View Institutional Ownership Trends for Clovis Oncology.
Who sold Clovis Oncology stock? Who is selling Clovis Oncology stock?
Who bought Clovis Oncology stock? Who is buying Clovis Oncology stock?
Clovis Oncology's stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Insight Capital Research & Management Inc., Hershey Trust Co., Legato Capital Management LLC, Bank of Montreal Can and Aperio Group LLC. View Insider Buying and Selling for Clovis Oncology.
How do I buy Clovis Oncology stock?
Shares of Clovis Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clovis Oncology's stock price today?
One share of Clovis Oncology stock can currently be purchased for approximately $87.04.
MarketBeat Community Rating for Clovis Oncology (NASDAQ CLVS)MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Clovis Oncology (NASDAQ:CLVS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 6 Hold Ratings, 10 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.63) |
| Consensus Price Target: | $79.50 (8.66% downside) |
Analysts' Ratings History for Clovis Oncology (NASDAQ:CLVS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/18/2017 | Credit Suisse Group | Set Price Target | Buy | $107.00 | Low |  |
| 7/7/2017 | Gabelli | Initiated Coverage | Buy | $125.00 | High | |
| 6/23/2017 | Oppenheimer Holdings, Inc. | Initiated Coverage | Market Perform | | Low | |
| 6/22/2017 | Cann | Initiated Coverage | Market Perform | | Low | |
| 6/22/2017 | SunTrust Banks, Inc. | Reiterated Rating | Buy | | Low | |
| 6/20/2017 | J P Morgan Chase & Co | Reiterated Rating | Overweight | $72.00 -> $111.00 | High | |
| 6/20/2017 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Neutral | $67.00 -> $90.00 | High | |
| 6/20/2017 | Janney Montgomery Scott | Upgrade | Neutral -> Buy | | Medium | |
| 6/20/2017 | Bank of America Corporation | Lower Price Target | Buy | $103.00 -> $75.00 | High | |
| 6/20/2017 | Morgan Stanley | Reiterated Rating | Overweight | $79.00 | High | |
| 6/19/2017 | Leerink Swann | Boost Price Target | Outperform | $85.00 -> $114.00 | High | |
| 6/19/2017 | Stifel Nicolaus | Boost Price Target | Buy | $86.00 -> $125.00 | High | |
| 6/19/2017 | Chardan Capital | Upgrade | Sell -> Neutral | $36.00 -> $50.00 | High | |
| 3/28/2017 | Piper Jaffray Companies | Set Price Target | Buy | $77.00 | Low | |
| 12/21/2016 | WallachBeth Capital | Boost Price Target | Hold | $22.00 -> $49.00 | N/A | |
| 8/24/2016 | Mizuho | Boost Price Target | Neutral | $15.00 -> $23.00 | N/A | |
(Data available from 7/25/2015 forward)
Earnings History for Clovis Oncology (NASDAQ:CLVS)Earnings History by Quarter for Clovis Oncology (NASDAQ CLVS)(Data available from 1/1/2011 forward)
Earnings Estimates for Clovis Oncology (NASDAQ:CLVS)2017 EPS Consensus Estimate: ($4.89)
2018 EPS Consensus Estimate: ($2.18)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($1.53) | ($1.53) | ($1.53) |
| Q2 2017 | 3 | ($1.30) | ($1.18) | ($1.23) |
| Q3 2017 | 3 | ($1.16) | ($1.05) | ($1.11) |
| Q4 2017 | 3 | ($1.13) | ($0.87) | ($1.02) |
| Q1 2018 | 1 | ($0.67) | ($0.67) | ($0.67) |
| Q2 2018 | 1 | ($0.53) | ($0.53) | ($0.53) |
| Q3 2018 | 1 | ($0.53) | ($0.53) | ($0.53) |
| Q4 2018 | 1 | ($0.45) | ($0.45) | ($0.45) |
(Data provided by Zacks Investment Research)
Dividend History for Clovis Oncology (NASDAQ:CLVS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Clovis Oncology (NASDAQ:CLVS)Insider Ownership Percentage: 17.40%
Institutional Ownership Percentage: 89.61%
Insider Trades by Quarter for Clovis Oncology (NASDAQ:CLVS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/17/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $91.56 | $274,680.00 | |
| 6/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $61.82 | $185,460.00 | |
| 5/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $47.39 | $142,170.00 | |
| 4/17/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $56.02 | $168,060.00 | |
| 3/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $66.99 | $200,970.00 | |
| 11/2/2015 | Erle T. Mast | CFO | Sell | 3,000 | $105.56 | $316,680.00 | |
| 10/28/2015 | Lindsey Rolfe | insider | Sell | 4,000 | $98.02 | $392,080.00 | |
| 10/15/2015 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $91.91 | $275,730.00 | |
| 10/5/2015 | Lindsey Rolfe | insider | Sell | 4,000 | $93.04 | $372,160.00 | |
| 10/1/2015 | Erle T. Mast | CFO | Sell | 3,000 | $90.22 | $270,660.00 | |
| 9/18/2015 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $112.56 | $337,680.00 | |
| 9/1/2015 | Erle T. Mast | CFO | Sell | 3,000 | $79.51 | $238,530.00 | |
| 7/1/2015 | Erle T Mast | CFO | Sell | 3,000 | $85.70 | $257,100.00 | |
| 6/1/2015 | Erle T Mast | CFO | Sell | 3,000 | $88.78 | $266,340.00 | |
| 5/15/2015 | M James Barrett | Director | Sell | 2,424 | $92.43 | $224,050.32 | |
| 4/1/2015 | Erle T Mast | CFO | Sell | 3,000 | $71.25 | $213,750.00 | |
| 3/9/2015 | Erle T Mast | CFO | Sell | 9,000 | $78.84 | $709,560.00 | |
| 3/5/2015 | James C Blair | Director | Sell | 8,528 | $77.70 | $662,625.60 | |
| 1/16/2015 | Steven L Hoerter | Insider | Sell | 10,000 | $67.00 | $670,000.00 | |
| 12/11/2013 | Erle Mast | CFO | Sell | 50,000 | $52.78 | $2,639,000.00 | |
| 12/5/2013 | Thorlef Spickschen | Director | Sell | 9,000 | $56.10 | $504,900.00 | |
| 6/5/2013 | Andrew R Allen | Insider | Sell | 22,594 | $68.54 | $1,548,592.76 | |
| 6/4/2013 | M James Barrett | Director | Sell | 2,483 | $70.80 | $175,796.40 | |
| 6/4/2013 | Parters Vii L P Domain | Major Shareholder | Sell | 159,192 | $64.58 | $10,280,619.36 | |
| 6/4/2013 | Steven L Hoerter | Insider | Sell | 10,000 | $73.06 | $730,600.00 | |
| 3/6/2013 | Parters Vii L P Domain | Major Shareholder | Sell | 250,000 | $24.59 | $6,147,500.00 | |
| 8/16/2012 | Edward J Mckinley | Director | Buy | 9,701 | $15.50 | $150,365.50 | |
(Data available from 1/1/2013 forward)
Headline Trends for Clovis Oncology (NASDAQ:CLVS)
Latest Headlines for Clovis Oncology (NASDAQ:CLVS)
| Source: |
|
| Date | Headline |
|---|
 | Clovis Oncology, Inc. (NASDAQ:CLVS) PT Set at $107.00 by Credit Suisse Group
www.americanbankingnews.com - July 20 at 12:58 AM |
| Clovis Oncology, Inc. (CLVS) Raised to "Buy" at Vetr Inc.
www.americanbankingnews.com - July 20 at 12:26 AM |
 | 3 Stocks at 52-Week Highs Still Worth Buying
finance.yahoo.com - July 18 at 6:48 PM |
| Clovis Oncology, Inc. (NASDAQ:CLVS) Insider Gillian C. Ivers-Read Sells 3,000 Shares
www.americanbankingnews.com - July 17 at 10:14 PM |
| $13.65 Million in Sales Expected for Clovis Oncology, Inc. (NASDAQ:CLVS) This Quarter
www.americanbankingnews.com - July 16 at 8:00 AM |
| Analysts Expect Clovis Oncology, Inc. (NASDAQ:CLVS) to Post -$1.29 EPS
www.americanbankingnews.com - July 14 at 6:20 PM |
 | Clovis (CLVS) Focuses on Rubraca Launch and Label Expansion ... - Nasdaq
www.nasdaq.com - July 14 at 4:26 AM |
| Clovis (CLVS) Focuses on Rubraca Launch and Label Expansion
finance.yahoo.com - July 13 at 6:23 PM |
| Zacks Investment Research Lowers Clovis Oncology, Inc. (NASDAQ:CLVS) to Hold
www.americanbankingnews.com - July 13 at 3:06 PM |
 | Here's Why Clovis Oncology Inc. Jumped 70% in June - Motley Fool
www.fool.com - July 8 at 4:57 PM |
| Here's Why Clovis Oncology Inc. Jumped 70% in June
finance.yahoo.com - July 8 at 9:52 AM |
| Clovis Oncology, Inc. (NASDAQ:CLVS) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 7 at 11:58 AM |
| Clovis Oncology, Inc. (NASDAQ:CLVS) Coverage Initiated at Gabelli
www.americanbankingnews.com - July 7 at 10:52 AM |
| Noteworthy ETF Outflows: XBI, CLVS, EXEL, ALXN - Nasdaq
www.nasdaq.com - July 5 at 5:58 PM |
| Stock Traders Purchase Large Volume of Clovis Oncology Call Options (CLVS)
www.americanbankingnews.com - July 5 at 7:16 AM |
| This Rebounding Pharma Stock May Launch Another Breakout Move
finance.yahoo.com - June 30 at 5:24 PM |
| Is It Too Late to Buy Clovis Oncology Stock?
www.fool.com - June 27 at 4:00 PM |
| Equities Analysts Issue Forecasts for Clovis Oncology, Inc.'s Q2 2017 Earnings (CLVS)
www.americanbankingnews.com - June 26 at 7:08 AM |
| Clovis Oncology, Inc. (CLVS) to Post Q2 2017 Earnings of ($1.18) Per Share, Oppenheimer Holdings Forecasts
www.americanbankingnews.com - June 26 at 7:08 AM |
 | What To Expect From Clovis Oncology Following Rubraca Approval - Benzinga
www.benzinga.com - June 24 at 3:02 AM |
| Healthcare ETF (IYH) Hits New 52-Week High
finance.yahoo.com - June 23 at 4:58 PM |
| What To Expect From Clovis Oncology Following Rubraca Approval
feeds.benzinga.com - June 23 at 1:38 PM |
| Clovis Oncology, Inc. (CLVS) Earns Market Perform Rating from Analysts at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - June 23 at 9:06 AM |
 | Clovis Oncology (CLVS) Prices Upsized Offering at $88/Share
www.streetinsider.com - June 22 at 9:48 PM |
| Clovis Oncology, Inc. (CLVS) Coverage Initiated at Cann
www.americanbankingnews.com - June 22 at 5:27 PM |
| Clovis Oncology commencing $250 million stock offering
finance.yahoo.com - June 22 at 4:39 PM |
| Clovis Oncology Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock
finance.yahoo.com - June 22 at 11:05 AM |
| Clovis Oncology, Inc. (CLVS) Worth a Look: Stock Jumps 6.3%
finance.yahoo.com - June 22 at 11:05 AM |
| $13.65 Million in Sales Expected for Clovis Oncology, Inc. (CLVS) This Quarter
www.americanbankingnews.com - June 22 at 10:24 AM |
| SunTrust Banks, Inc. Reaffirms Buy Rating for Clovis Oncology, Inc. (CLVS)
www.americanbankingnews.com - June 22 at 10:22 AM |
| BidaskClub Upgrades Clovis Oncology, Inc. (CLVS) to Buy
www.americanbankingnews.com - June 21 at 8:18 PM |
| Q3 2017 EPS Estimates for Clovis Oncology, Inc. (CLVS) Lifted by Leerink Swann
www.americanbankingnews.com - June 21 at 8:36 AM |
| Clovis Oncology (CLVS) Prices Upsized Offering at $88/Share - StreetInsider.com
www.streetinsider.com - June 20 at 10:02 PM |
| Clovis Oncology Announces Upsizing and Pricing of Public Offering of Common Stock
finance.yahoo.com - June 20 at 10:02 PM |
| Brokerages Expect Clovis Oncology, Inc. (CLVS) to Announce -$1.20 EPS
www.americanbankingnews.com - June 20 at 4:10 PM |
| Clovis Addresses Some Of The Company's Biggest Controversies
feeds.benzinga.com - June 20 at 3:55 PM |
| J P Morgan Chase & Co Reiterates "Overweight" Rating for Clovis Oncology, Inc. (CLVS)
www.americanbankingnews.com - June 20 at 12:28 PM |
| Clovis Oncology, Inc. (CLVS) Stock Rating Upgraded by Janney Montgomery Scott
www.americanbankingnews.com - June 20 at 7:58 AM |
| Mid-Afternoon Market Update: Crude Oil Down Over 1%; Clovis Oncology Shares Spike Higher - Nasdaq
www.nasdaq.com - June 20 at 5:24 AM |
 | Clovis Oncology Inc. (CLVS) Is Pulling Back After Stock Offering
www.rttnews.com - June 20 at 12:23 AM |
| Biotech stocks are having their best day since February
finance.yahoo.com - June 20 at 12:22 AM |
| Clovis Oncology Announces Proposed Offering of Common Stock
finance.yahoo.com - June 20 at 12:22 AM |
| Clovis Oncology to launch $250 mln stock offering
finance.yahoo.com - June 20 at 12:22 AM |
| Mid-Afternoon Market Update: Crude Oil Down Over 1%; Clovis Oncology Shares Spike Higher - Benzinga
www.benzinga.com - June 19 at 7:22 PM |
 | Why Clovis Oncology Inc (CLVS) Stock Just Shot 50% Higher - Investorplace.com
investorplace.com - June 19 at 7:22 PM |
| Here's what's behind the biotech breakout
finance.yahoo.com - June 19 at 7:22 PM |
| Clovis Oncology Target of Unusually High Options Trading (CLVS)
www.americanbankingnews.com - June 19 at 5:38 PM |
| Clovis Oncology, Inc. (CLVS) Given New $114.00 Price Target at Leerink Swann
www.americanbankingnews.com - June 19 at 4:28 PM |
| Mid-Afternoon Market Update: Crude Oil Down Over 1%; Clovis Oncology Shares Spike Higher
feeds.benzinga.com - June 19 at 4:22 PM |
| Clovis Oncology's Rubraca Notches Key Trial Win
www.fool.com - June 19 at 2:34 PM |
Clovis Oncology (CLVS) Chart for Tuesday, July, 25, 2017
